RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Immunoprecise Antibodies Stock

Immunoprecise Antibodies P/S 2024

Immunoprecise Antibodies P/S

1.49

Ticker

IPA

ISIN

CA45257F2008

WKN

A2QJEC

As of Sep 27, 2024, Immunoprecise Antibodies's P/S ratio stood at 1.49, a -71.35% change from the 5.2 P/S ratio recorded in the previous year.

The Immunoprecise Antibodies P/S history

Immunoprecise Antibodies Aktienanalyse

What does Immunoprecise Antibodies do?

Immunoprecise Antibodies Ltd is a leading company in the development of antibodies and antibody-based solutions for the pharmaceutical and biotech industry. The company was founded in 2015 as a spin-off from the University of Victoria in Canada and has since experienced rapid growth, expanding into other countries such as the USA, Europe, and Asia. The company's unique business model is based on three pillars: providing innovative research services tailored to the needs of the pharmaceutical and biotech industry, offering a broad portfolio of antibody products for research and diagnostics, and developing a pipeline of new therapeutics currently undergoing clinical trials. The core business of Immunoprecise Antibodies Ltd is the manufacturing of antibodies and antibody-based solutions for research and diagnostics. The company offers a range of innovative services, including antibody engineering, production and purification, and characterization. The research services are provided by an experienced team of scientists and experts in the field of antibody research who work closely with customers to meet their specific needs. In addition, the company has a wide range of antibody products available for various applications in research and diagnostics, including protein quantification, immunohistochemistry, cancer antigen detection, influenza diagnostics, and many others. Immunoprecise Antibodies Ltd has also developed a pipeline of new therapeutics, including antibodies against cancer, inflammation, and infectious diseases, which are currently undergoing clinical trials. The company collaborates closely with leading pharmaceutical and biotech companies to advance the latest developments in this field. To enable better focus and specialization, Immunoprecise Antibodies Ltd is divided into six divisions: humanization/antibody engineering, antibody production, antibody characterization, immunohistochemistry, therapeutics development, and process development. These divisions are strategically designed to cover the needs of customers and facilitate an effective supply chain for antibody production and development. Immunoprecise Antibodies Ltd is a young and dynamic company with a strong focus on innovation and customer satisfaction. It has earned an excellent reputation in the industry and is regarded as a valuable partner for antibody research and development by leading pharmaceutical and biotech companies. The company's goal is to remain a key player in the field of antibody research and continue developing innovative solutions for the pharmaceutical and biotech industry. Immunoprecise Antibodies ist eines der beliebtesten Unternehmen auf Eulerpool.com.

P/S Details

Decoding Immunoprecise Antibodies's P/S Ratio

Immunoprecise Antibodies's Price to Sales (P/S) Ratio is a crucial financial metric that measures the company's market valuation relative to its total sales revenue. It's calculated by dividing the company's market capitalization by its total sales over a specific period. A lower P/S ratio can indicate that the company is undervalued, while a higher ratio may suggest overvaluation.

Year-to-Year Comparison

Comparing Immunoprecise Antibodies's P/S ratio yearly provides insights into how the market perceives the company’s value relative to its sales. An increasing ratio over time can indicate growing investor confidence, while a decreasing trend might reflect concerns about the company’s revenue generation capabilities or market conditions.

Impact on Investments

The P/S ratio is instrumental for investors evaluating Immunoprecise Antibodies's stock. It offers insights into the company’s efficiency in generating sales and its market valuation. Investors use this ratio to compare similar companies within the same industry, aiding in selecting stocks that offer the best value for investment.

Interpreting P/S Ratio Fluctuations

Variations in Immunoprecise Antibodies’s P/S ratio can result from changes in the stock price, sales revenue, or both. Understanding these fluctuations is crucial for investors to evaluate the company’s current valuation and future growth potential, aligning their investment strategies accordingly.

Frequently Asked Questions about Immunoprecise Antibodies stock

What is the price-to-earnings ratio of Immunoprecise Antibodies?

The price-earnings ratio of Immunoprecise Antibodies is currently 1.49.

How has the price-earnings ratio of Immunoprecise Antibodies changed compared to last year?

The price-to-earnings ratio of Immunoprecise Antibodies has increased by -71.35% fallen (meaning "decreased" or "dropped") compared to last year.

What consequences does a high price-earnings ratio have for investors?

A high price-to-earnings ratio indicates that the company's stock is relatively expensive and investors may potentially achieve a lower return.

What does a low price-earnings ratio mean?

A low price-earnings ratio means that the company's stock is relatively cheap and investors may potentially achieve a higher return.

Is the price-earnings ratio of Immunoprecise Antibodies high compared to other companies?

Yes, the price-to-earnings ratio of Immunoprecise Antibodies is high compared to other companies.

How does an increase in the price-earnings ratio of Immunoprecise Antibodies affect the company?

An increase in the price-earnings ratio of Immunoprecise Antibodies would lead to a higher market capitalization of the company, which in turn would lead to a higher valuation of the company.

How does a reduction in the price-to-earnings ratio of Immunoprecise Antibodies affect the company?

A decrease in the price-earnings ratio of Immunoprecise Antibodies would result in a lower market capitalization of the company, which in turn would lead to a lower valuation of the company.

What are some factors that influence the price-earnings ratio of Immunoprecise Antibodies?

Some factors that influence the price-earnings ratio of Immunoprecise Antibodies are the company's growth, financial position, industry development, and the overall economic situation.

How much dividend does Immunoprecise Antibodies pay?

Over the past 12 months, Immunoprecise Antibodies paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Immunoprecise Antibodies is expected to pay a dividend of 0 CAD.

What is the dividend yield of Immunoprecise Antibodies?

The current dividend yield of Immunoprecise Antibodies is .

When does Immunoprecise Antibodies pay dividends?

Immunoprecise Antibodies pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Immunoprecise Antibodies?

Immunoprecise Antibodies paid dividends every year for the past 0 years.

What is the dividend of Immunoprecise Antibodies?

For the upcoming 12 months, dividends amounting to 0 CAD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Immunoprecise Antibodies located?

Immunoprecise Antibodies is assigned to the 'Health' sector.

Wann musste ich die Aktien von Immunoprecise Antibodies kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Immunoprecise Antibodies from 9/27/2024 amounting to 0 CAD, you needed to have the stock in your portfolio before the ex-date on 9/27/2024.

When did Immunoprecise Antibodies pay the last dividend?

The last dividend was paid out on 9/27/2024.

What was the dividend of Immunoprecise Antibodies in the year 2023?

In the year 2023, Immunoprecise Antibodies distributed 0 CAD as dividends.

In which currency does Immunoprecise Antibodies pay out the dividend?

The dividends of Immunoprecise Antibodies are distributed in CAD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Immunoprecise Antibodies

Our stock analysis for Immunoprecise Antibodies Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Immunoprecise Antibodies Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.